Downstream

Virtual Demonstration of the BioSMB Multi-Column Chromatography Platform

This webinar provides a virtual demonstration of the BioSMB multi-column chromatography platform — a fully scalable single-use solution that reduces resin usage and enables manufacturers to explore continuous processing. The demo starts with an overview of the BioSMB PD system for small-scale manufacturing and then continues with the BioSMB Process systems for clinical and commercial manufacturing. Click here to watch this virtual demonstration.

Crude Sample Analysis in Process Development: Time and Cost Savings

This overview highlights a few examples from drug discovery and process development where the Octet® system demonstrated a significant reduction in the analysis time over ELISA and HPLC by eliminating the need for purification, while still achieving high accuracy and precision. The total assay times were dramatically reduced with fewer assay steps and less labor time involved. The easy and versatile, fully integrated Octet® assay has additional advantages over other label-free technologies like SPR, where sample washing steps are required.…

Expanding Applications in Downstream Biologics Characterization: Stability, Formulations and Aggregation Studies using Octet®

Structure is an important characteristic for protein activity and function. Structural alterations due to protein mis-folding, denaturation or unfavorable conditions can lead to the formation of aggregate species that can affect the efficacy and safety of biologic drug candidates. While many biophysical analytical tools are well suited for detecting these aggregates, few offer a combination of structural and functions assessment in the same system. Sartorius’ Octet® platform is an easy-to-use analytical tool that can detect the presence of aggregated species…

FAQs: Challenging host cell protein assays for improved risk mitigation

Host cell proteins (HCP) are critical to quality control in biologics development. If left unremoved, they can cause immunogenic responses and reduce drug efficacy. In our last webinar we shared Cytiva’s strategy for designing a comprehensive HCP risk mitigation strategy. We discussed how to challenge your assays early to ensure accurate measurements, build confidence, and reduce the risk of unexpected HCP levels. Our HCP experts highlighted and responded to the most common questions raised around host cell protein assays. Want…

Keep Your HCPs Under Control

When it comes to manufacturing biologics, managing host cell protein (HCP) levels is essential. A robust HCP strategy can help protect both your timeline and budget. Cytiva understands the challenges researchers face in HCP detection, quantification, and removal. We offer an end-to-end solution for HCP management, and our experts will work with you to find the right strategy tailored to your needs. To get started now, check out our knowledge center for expertise and advice on enhancing your HCP strategy.

Your Guide to Efficiently Develop Antibody-Based Therapeutics

This eBook presents various techniques used to measure the stability of antibody-based biotherapeutics. The authors address the ins-and-outs of monoclonal antibody (MAb) formulation, cover Investigational New Drug (IND) and New Drug Application (NDA) filing timelines, and explain how storage conditions affect MAb stability. Monoclonal antibodies have been used in therapeutics for more than 30 years. Efforts to further develop and optimize better MAb-based biotherapeutics are increasing as they have become increasingly popular for the treatment and prevention of many diseases…

Future Proof Your HCP Strategy

Future proof your HCP strategy. Four questions to help you decide if your HCP analysis data is ready for next phase approval. Host cell proteins (HCPs) are a primary source of impurities in biologics development. Scientists must detect and remove HCPs to ensure patient safety and meet regulatory guidelines. If previously undetected HCPs are found in later phases of clinical trials, scientists will need to redesign the drug substance purification strategy – adding financial and time costs that can create…

Do Not Let HCPs Delay Your Biologics Route to Market

The stakes are high in biologics development, especially in host cell protein (HCP) analysis. Regulatory bodies have rules and suggested strategies for HCP analysis and reporting, and it is likely that removing HCPs is a key concern in your process development. Ultimately, the accuracy of monitoring and success of purifying your biologic of these HCPs can make or break your product. Get it wrong and it could delay your development cycle. In this blog, we outline strategies to optimize your…

Ensuring Everything is A-OK at AKBA

Accurately and reliably producing pharmaceuticals and biotherapeutics is one of the most important – and challenging – tasks in the world of manufacturing. Any misstep in the production process will lead to the creation of a substandard end product that can do substantial harm to the user. That’s why the processes used in these production chains – things like inline buffer formulation (IBF) and virus filtration – must be completed with no deviation from accepted norms. For Asahi Kasei Bioprocess…

Confidence in Host Cell Protein (HCP) Coverage Assays with Differential Gel Approaches

Enzyme-linked immunosorbent assays (ELISAs) are critical to detecting and removing host cell proteins (HCPs), a primary source of impurities in biologics development. Scientists must validate HCP ELISAs to ensure patient safety and meet regulatory guidelines – but different coverage assays come with different challenges, limitations, and benefits. The US Pharmacopeia recommends 2D differential gel electrophoresis (DIGE) combined with Western blot or immunoaffinity approaches, and labs might not be able to gain the full benefits of DIGE without significantly altering current…